Twenty-First Century Pathology Sign-Out

Clinics in Laboratory Medicine

Volumn 32, Issue 4, 2012, Pages 639-650

  Tomlins, Scott ^a   Robinson, Daniel ^a   Penny, Robert J ^a,b   Hess, Jay L ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b International Genomics Consortium   (United States)

Author keywords

Future of pathology; Molecular diagnostics; Personalized medicine

Indexed keywords

BREAST CANCER; DECISION SUPPORT SYSTEM; FLUORESCENCE IN SITU HYBRIDIZATION; FOOD AND DRUG ADMINISTRATION; GENE EXPRESSION; GENE MUTATION; HEMATOLOGIC MALIGNANCY; HIGH THROUGHPUT SEQUENCING; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG CANCER; PATHOLOGY; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; REVIEW; SOLID TUMOR; THYROID MEDULLARY CARCINOMA;

HUMANS; INDIVIDUALIZED MEDICINE; MOLECULAR DIAGNOSTIC TECHNIQUES; PATHOLOGY, CLINICAL;

EID: 84867681895     PISSN: 02722712     EISSN: 15579832     Source Type: Journal    
DOI: 10.1016/j.cll.2012.07.002     Document Type: Review

References (24)

1. Grasso C.S., Wu Y.M., Robinson D.R., et al. The mutational landscape of lethal castrate resistant prostate cancer. Nature 2012, 487(7406):239-243.
2. Taylor B.S., Schultz N., Hieronymus H., et al. Integrative genomic profiling of human prostate cancer. Cancer Cell 2010, 18(1):11-22.
3. Tomlins S.A., Mehra R., Rhodes D.R., et al. Integrative molecular concept modeling of prostate cancer progression. Nat Genet 2007, 39(1):41-51.
4. Maher C.A., Kumar-Sinha C., Cao X., et al. Transcriptome sequencing to detect gene fusions in cancer. Nature 2009, 458(7234):97-101.
5. Maher C.A., Palanisamy N., Brenner J.C., et al. Chimeric transcript discovery by paired-end transcriptome sequencing. Proc Natl Acad Sci U S A 2009, 106(30):12353-12358.
6. Prensner J.R., Iyer M.K., Balbin O.A., et al. Transcriptome sequencing across a prostate cancer cohort identifies PCAT-1, an unannotated lincRNA implicated in disease progression. Nat Biotechnol 2011, 29(8):742-749.
7. Berger M.F., Lawrence M.S., Demichelis F., et al. The genomic complexity of primary human prostate cancer. Nature 2011, 470(7333):214-220.
8. Fong P.C., Boss D.S., Yap T.A., et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 2009, 361(2):123-134.
9. Roberts P.J., Bisi J.E., Strum J.C., et al. Multiple roles of cyclin-dependent kinase 4/6 inhibitors in cancer therapy. J Natl Cancer Inst 2012, 104(6):476-487.
10. Attard G., Reid A.H., Olmos D., et al. Antitumor activity with CYP17 blockade indicates that castration-resistant prostate cancer frequently remains hormone driven. Cancer Res 2009, 69(12):4937-4940.
11. Shen M.M., Abate-Shen C. Molecular genetics of prostate cancer: new prospects for old challenges. Genes Dev 2010, 24(18):1967-2000.
12. Attard G., de Bono J.S. Utilizing circulating tumor cells: challenges and pitfalls. Curr Opin Genet Dev 2011, 21(1):50-58.
13. Sarker D., Reid A.H., Yap T.A., et al. Targeting the PI3K/AKT pathway for the treatment of prostate cancer. Clin Cancer Res 2009, 15(15):4799-4805.
14. Cakir M., Grossman A.B. Medullary thyroid cancer: molecular biology and novel molecular therapies. Neuroendocrinology 2009, 90(4):323-348.
15. Pao W., Hutchinson K.E. Chipping away at the lung cancer genome. Nat Med 2012, 18(3):349-351.
16. Wells S.A., Robinson B.G., Gagel R.F., et al. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. J Clin Oncol 2012, 30(2):134-141.
17. Roychowdhury S., Iyer M.K., Robinson D.R., et al. Personalized oncology through integrative high-throughput sequencing: a pilot study. Sci Transl Med 2011, 3(111):111-121.
18. Cheung H.W., Cowley G.S., Weir B.A., et al. Systematic investigation of genetic vulnerabilities across cancer cell lines reveals lineage-specific dependencies in ovarian cancer. Proc Natl Acad Sci U S A 2011, 108(30):12372-12377.
19. Brough R., Frankum J.R., Sims D., et al. Functional viability profiles of breast cancer. Cancer Discov 2011, 1(3):260-273.
20. Garnett M.J., Edelman E.J., Heidorn S.J., et al. Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature 2012, 483(7391):570-575.
21. Gerlinger M., Rowan A.J., Horswell S., et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 2012, 366(10):883-892.
22. Baron R.J. What's keeping us so busy in primary care? A snapshot from one practice. N Engl J Med 2010, 362(17):1632-1636.
23. Valenstein P.N. Formatting pathology reports: applying four design principles to improve communication and patient safety. Arch Pathol Lab Med 2008, 132(1):84-94.
24. Hess J.L. What hematopathology tells us about the future of pathology informatics. Arch Pathol Lab Med 2009, 133(6):908-911.